Loading
Ikonisys Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 20 Feb 2025.
Ikonisys: what insiders have been doing
Ikonisys, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to AMF. From 18 October 2025 to 18 October 2026, the disclosure feed for Ikonisys logged 16 filings by 1 insider.
Only sales appear on the open market, 14 sales in all totalling €866k, filed by 1 insider. One trade stands out by size: a sale of €96k from Mario Mauri, disclosed on 24 February 2026, or 0.41% of market capitalisation.
For context, the typical company on the same exchange (median of 316 companies) published 6 filings over the same period, against 16 filings here. Looking back to 2022, when coverage begins, insiders filed 1 purchase and 30 sales.
The median gap between a trade and its publication by AMF is 4 days. For comparison, MAR article 19 gives managers three business days to notify a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. Source: insider filings from AMF. Past trades are no guide to future returns.
Insider Decl.
34
Thresholds
n/a
Buy Volume
€2,175
1 ops. · all time
Sell Volume
€4M
30 ops. · all time
Who traded when
BuySaleMario Mauri1 buy25 sales
Since the insiders bought
- +6.0%Entry €1.51 · Close at T+365 €1.60
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 18,893 of 24,148 companies
32.2
score / 100
Value16
Quality48
FCF yld-6.3%
Earn yld-19%
EV/EBITDA·
ROE-16%
Gross mgn65%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€1.44
Analyst consensus
1 analysts1.00/5
€2.30Target €2.30(+60%)€2.30
Income statement
Revenue€1.4M
Gross profit€897k65% margin
EBITDA-€1.1M-82% margin
Net income-€4.2M-256.3% margin
Valuation
PER (forward)-57.6x
P/Book1.1x
Beta0.65
Balance sheet & cash
Market cap€22.8M
Total debt€3.3M
Free Cash Flow-€1.4M
Debt / Equity17%
Profitability & ownership
ROE-16.4%
ROA-6.1%
% insiders17.8%
% institutions45.4%
Last declaration on 10 August 2026
Declarations34 total
58,000 shares@ €1.600.41% mcap2.0% of flowActionHors plateforme de négociationISIN FR00140048X22026DD1132776
20,000 shares@ €1.460.13% mcap0.6% of flowActionHors plateforme de négociationISIN FR00140048X22026DD1102861
60,000 shares@ €1.520.39% mcap2.0% of flowActionHors plateforme de négociationISIN FR00140048X22026DD1098358
60,000 shares@ €1.600.41% mcap2.1% of flowActionHors plateforme de négociationISIN FR00140048X22026DD1096495
40,625 shares@ €1.600.28% mcap1.4% of flowActionHors plateforme de négociationISIN FR00140048X22026DD1096497
50,000 shares@ €1.551.7% of flowActionHors plateforme de négociationISIN FR00140048X22026DD1094022
50,000 shares@ €1.551.7% of flowActionHors plateforme de négociationISIN FR00140048X22026DD1091512
50,000 shares@ €1.511.6% of flowActionHors plateforme de négociationISIN FR00140048X22026DD1089297
15,850 shares@ €1.65430.6% of flowActionEuronext Growth ParisISIN FR00140048X22025DD1086219
2,050 shares@ €1.600.1% of flowActionEuronext Growth ParisISIN FR00140048X22025DD1086220
25,072 shares@ €1.500.8% of flowActionEuronext Growth ParisISIN FR00140048X22025DD1086215
417,172 shares@ €1.5013.6% of flowActionEuronext Growth ParisISIN FR00140048X22025DD1086216
35,000 shares@ €1.501.1% of flowActionHors plateforme de négociationISIN FR00140048X22025DD1085342
40,000 shares@ €1.451.3% of flowActionHors plateforme de négociationISIN FR00140048X22025DD1072927
40,000 shares@ €1.411.2% of flowActionHors plateforme de négociationISIN FR00140048X22025DD1071691
44,952 shares@ €1.4461.4% of flowActionHors plateforme de négociationISIN FR00140048X22025DD1070363
38,343 shares@ €1.521.3% of flowActionHors plateforme de négociationISIN FR00140048X22025DD1054407
5,555 shares@ €1.450.2% of flowActionEuronext Growth ParisISIN FR00140048X22025DD1032799
133,334 shares@ €1.504.4% of flowActionEuronext Growth ParisISIN FR00140048X22025DD1036808
3,015 shares@ €1.510.1% of flowActionEuronext Growth ParisISIN FR00140048X22025DD1036645
14,500 shares@ €1.460.5% of flowActionEuronext Growth ParisISIN FR00140048X22025DD1027353
1,500 shares@ €1.450.0% of flowActionEuronext Growth ParisISIN FR00140048X22025DD1021213
Canonical exit: 18 May 2025 (T+90)
5,737 shares@ €1.5050.2% of flowActionHors plateforme de négociationISIN FR00140048X22025DD1021190
50,002 shares@ €1.581.7% of flowActionEuronext Growth ParisISIN FR00140048X22025DD1016991
70,000 shares@ €1.422.2% of flowActionHors plateforme de négociationISIN FR00140048X22024DD1011055
25 of 34 declarations
About Ikonisys
Ikonisys is a medtech company focused on automated cell-based diagnostics, with a strong specialization in oncology and rare-cell detection. Founded in New Haven, Connecticut, the group built its reputation around the proprietary Ikoniscope® digital microscope, a fully automated platform designed to detect, analyze and enumerate rare cells with high precision. Its core offering combines hardware, software and reagents, leveraging FISH (Fluorescence In Situ Hybridization) technology alongside cytology-oriented diagnostic workflows.
From a corporate history perspective, Ikonisys initially developed as a technology-driven diagnostics company focused on automating medical imaging and laboratory interpretation. A key milestone was its admission to trading on Euronext Growth Paris in 2021, which helped finance the expansion of the Ikoniscope platform in Europe and the United States. The company subsequently broadened its industrial scope through the acquisition of Hospitex International, strengthening its exposure to cytology and oncology diagnostics. By 2025-2026, the group has also been communicating under the Aliko Scientific identity, while continuing to use the Ikonisys brand for its technology and commercial solutions.
Read moreShow less
Its business model is centered on the sale of automated instruments, FISH diagnostic applications and related consumables, as well as liquid-based cytology and laboratory workflow automation solutions. The company highlights clinical applications across several cancer types, including bladder, breast, cervical, prostate and lung cancers, together with selected hematology applications. The value proposition is built on improving standardization, reducing operator dependence, increasing reproducibility and enhancing laboratory productivity.
Commercially, Ikonisys targets medical laboratories, hospitals and pathology networks in Europe and the United States, supported by an international footprint spanning Paris, Milan, Florence and New Haven. The company emphasizes its transatlantic presence and relies on distribution partnerships, industrial alliances and group synergies to expand market penetration. Notable facts include regulatory validation such as FDA clearances for certain applications, CE-marked products in Europe, and ongoing development of next-generation microscopes and AI-enabled applications intended to further automate cancer diagnostics.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
